ALK-Abelló (ALK) Q3 2024 earnings summary

Executive summary

• Achieved 18% organic revenue growth in Q3 2024, with strong performance across regions and product lines, especially tablets (29% global growth, 27% in Europe), and a rebound in JextⓇ sales.

• EBIT margin rose to 23%, driven by sales growth, gross margin improvements, and cost savings, aligning with financial targets.

• Strategic initiatives advanced, including the in-licensing of neffyⓇ nasal spray and ongoing clinical development in food and pediatric allergy.

• JextⓇ auto-injector sales fully recovered from prior supply shortages, contributing to growth.

• Optimization and resource reallocation efforts focused on high-impact European markets.

Financial highlights

• Q3 revenue reached DKK 1,313 million (+18% year-over-year); 9M revenue up 16% to DKK 4,038 million.

• EBIT for 9M 2024 rose 91% to DKK 886 million, with a margin of 21.9% versus 13.6% in 9M 2023.

• Gross margin improved to 64.3% (up from 63%); free cash flow for 9M reached DKK 425 million (up from DKK 51 million year-over-year).

• DKK 49 million in one-off costs included in 9M EBIT; Q3 EBIT included DKK 11 million in one-off costs.

• R&D expenses down 22% after major clinical trials; sales and marketing expenses up 8%, admin costs up 9%.

Outlook and guidance

• Full-year 2024 outlook confirmed: organic revenue growth of 14–16% and EBIT margin of 19–21%.

• Europe expected to lead with robust double-digit growth; North America and international markets to see single-digit growth.

• Gross margin projected to increase by more than 1 percentage point; R&D expenses to decline to around 10% of revenue.

• Q4 revenue growth anticipated to be lower than Q2 and Q3 due to shipment fluctuations and soft North America performance.

• 2024-25 initiation season expected to be average, better than 2022-23 but below 2023-24.